Prescription Omega-3-Acid Ethyl Esters for the Treatment of Very High Triglycerides
Abstract
Triglyceride (TG) levels can increase for numerous reasons, including a sedentary lifestyle, an unhealthy diet, especially one rich in refined carbohydrates, and comorbidities. According to the National Cholesterol Education Program (NCEP), the normal TG level is or = 500 mg/dL) should be promptly managed and treated to reach lipid treatment goals, as determined by the NCEP. Lowering TG levels is the primary management goal in these patients, while lowering low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol levels are secondary goals. Therapeutic lifestyle changes are often recommended initially for patients with elevated TGs; however, concomitant drug therapy is often required. Data show that intake of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) can significantly decrease serum TGs, along with plasma concentrations of certain lipoproteins. Omega-3-acid ethyl esters are available by prescription or as dietary supplements. Clinical trials in adult patients with VHTGs show that four 1 g capsules of prescription omega-3 fatty acids, which contain 465 mg of EPA and 375 mg of DHA per capsule, can effectively decrease TG levels by up to 45%, and is generally well tolerated.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
More recent studies of hypertriglyceridemia support an effect on LDL particle size.
“deed, such an effect on LDL particle size is supported by the results of more recent studies of HTG.”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [24]
Cites
Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review
Harris, W. S. (1989) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38310-3 · Cited by 1,127 · see citing works
Hypertriglyceridemia as a cardiovascular risk factor
Austin, M. A., Hokanson, J. E., & Edwards, K. L. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00031-9 · Cited by 1,066 · see citing works
Hypertriglyceridemia: its etiology, effects and treatment
Yuan, G., Al-Shali, K. Z., & Hegele, R. A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060963 · Cited by 624 · cited 4× · see citing works
“In patients who consume excess alcohol, an increase in TG levels is often caused by increased VLDL, sometimes with chylomicronemia.(11) Additionally, certain medications, such as ß-blockers, antipsychotic medications, estrogen, protease inhibitors, corticosteroids, and retinoids, can infl uence TG levels.”
BackgroundInfluentialHypertriglyceridemia and its pharmacologic treatment among US adults.
Ford, E. S., Li, C., Zhao, G., Pearson, W. S., & Mokdad, A. H. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.599 · Cited by 214 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Skulas-Ray, A. C., Wilson, P. W. F., Harris, W. S., Brinton, E. A., Kris-Etherton, P. M., Richter, C. K., Jacobson, T. A., Engler, M. B., Miller, M., Robinson, J. G., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000709 · Cited by 488 · see citing works
Self-citationGraham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377 · see citing works
Zand, J., Lanza, F., Garg, H. K., & Bryan, N. S. (2011) · Nutrition Research · doi:10.1016/j.nutres.2011.03.008 · Cited by 101 · see citing works
- Authors
- Sadovsky, R., & Kris-Etherton, P.
- Venue
- Postgraduate Medicine
- Publisher
- Informa UK Limited
- Published
- 2009-07
- Volume
- 121
- Issue
- 4
- Pages
- 145-153
- ISSN
- 0032-5481 (ISSN-L)
- 1941-9260
- OpenAlex
- W1976476281
- Cited by
- 28
- References
- 4
- Citations by year
- 2023: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 5 · 2013: 4 · 2012: 6
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Postgraduate Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- omega-3 acid ethyl esters, hypertriglyceridemia, eicosapentaenoic acid, docosahexaenoic acid, triglyceride lowering, lipid-lowering therapy, dietary supplements, therapeutic lifestyle changes, drug tolerability
- MeSH terms
- Diet, Docosahexaenoic Acids, Drug Combinations, Humans, Triglycerides, Eicosapentaenoic Acid, Hypertriglyceridemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review